EG
Therapeutic Areas
Anixa Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Breast Cancer Vaccine | Triple-Negative Breast Cancer (TNBC) - Treatment & Prevention | Phase 1 |
| Ovarian Cancer Vaccine | Ovarian Cancer - Treatment & Prevention | Discovery/Preclinical |
| CER-T Immunotherapy | Cancer (Undisclosed) | Preclinical/Discovery |
| Lung Cancer Vaccine | Lung Cancer | Discovery |
| Colon Cancer Vaccine | Colon Cancer | Discovery |
| Prostate Cancer Vaccine | Prostate Cancer | Discovery |
Leadership Team at Anixa Biosciences
AK
Amit Kumar, Ph.D.
Chairman & Chief Executive Officer
MC
Michael Catelani
President, COO & CFO
PD
Pamela D. Garzone, Ph.D.
Chief Development Officer
LT
Lew Titterton
Lead Independent Director
AB
Arnold Baskies, MD
Director
MS
Michael Shepard, Ph.D.
Scientific Advisor
JC
Jose Conejo-Garcia, MD, Ph.D.
Scientific Advisor
MD
Marco Davila, MD, Ph.D.
Scientific Advisor
DA
Daniel Abate-Daga, Ph.D.
Scientific Advisor
LK
Linda Kelley, Ph.D.
Scientific Advisor